hyperlipoproteinemia การใช้

Type I hyperlipoproteinemia usually presents in childhood with eruptive xanthomata and abdominal colic.
Defects in APOE result in familial dysbetalipoproteinemia aka type III hyperlipoproteinemia ( HLP III ), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron, VLDL and LDL remnants.
This pathology, however, is the second-most common disorder of the various hyperlipoproteinemias, with individuals with a heterozygotic predisposition of one in every 500 and individuals with homozygotic predisposition of one in every million.
Through catalysis, VLDL is converted to IDL and then to LDL . Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in LPL are linked to many disorders of lipoprotein metabolism.
As PCSK9 binds to LDLR, which prevents the removal of LDL-particles from the blood plasma, several studies have determined the potential use of PCSK9 inhibitors in the treatment of hyperlipoproteinemia ( commonly called hypercholesterolemia ).